“Biopreservation Market Report is set to have rapid growth due to consistent drug developments, advent of advanced therapies in the field of biomedical research and significant rise in patient base requiring high-end treatment for chronic diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopreservation Market Forecast 2019-2029: By Product (Equipment, Media, LIMS), By Application (Regenerative Medicine, Bio-banking, Drug Discovery), By Cell Provider, Regional And Segment Forecasts

The global biopreservation market is poised for rapid growth between 2019 and 2029. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.

An increase in healthcare costs is also expected to improve access to quality health care and advanced products, which include biopreservation facilities, thus expanding growth prospects. In addition, hospitals, gene banks and biobanks, which are significant end users for this market, are encouraging key players to develop technologically advanced biopreservation products to improve patient outcomes.

The presence of government health initiatives that provide funds, grants and research contracts have led to an accelerated growth of research and development activities carried out by various companies. This, in turn, has led to the expansion of the possibility of adopting advanced bioconservation services, which is foreseen for the rate of fuel penetration during the forecast period.

Technological advances in biopreservation processes are also important growth factors that contribute to the market. Advances include the change in the formulation of hypothermic conservation solutions, next-generation cryopreservation solutions and design and integration with nanoscale technologies. These technological updates have led to the conservation and long-term storage of complex organs and tissues of great importance in regenerative medicine and organ transplantation.

Leading companies featured in the report include BioLife Solutions Inc., BioCision, Biomatrica, Chart MVE Biomedical, TissueGene, LabVantage Solutions, Panasonic Biomedical, Qiagen, Taylor-Wharton Cryogenics and Thermo Fisher Scientific

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever